VolitionRx Releases New Study Showing Prognostic Value of Nu.Q Cancer Assay in Lung Cancer Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 19 hours ago
0mins
VolitionRx announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly. The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence" has been written in conjunction with researchers and clinicians at the Hospices Civils de Lyon, France's second largest university hospital system, and is currently under peer review. Dr Andrew Retter, Medical Consultant, Volition said: "We have worked closely with the Lyon team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q in the management of cancer patients. These results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care"
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.350
Low
1.50
Averages
2.25
High
3.00
Current: 1.350
Low
1.50
Averages
2.25
High
3.00
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VolitionRx Partners with Sysmex for Diagnostic Optimization
- Strategic Collaboration: VolitionRx Limited (VNRX) has entered into a strategic collaboration agreement with global in vitro diagnostics leader Sysmex Corporation (SSMXF) to optimize Volition's proprietary Nu.Q® NETs H3.1 assay for automated processing on Sysmex's specialized testing platforms.
- Significant Market Potential: According to internal estimates, Volition projects the total addressable market for the specialized Nu.Q® NETs assay to be approximately $3.8 billion, indicating a vast opportunity for this technology in the healthcare market.
- Targeted Disease Focus: The partnership will primarily target diseases closely associated with NETosis, the process by which Neutrophil Extracellular Traps are released, which serves as a critical biomarker implicated in a wide range of acute and chronic conditions, including sepsis, thrombosis, and hemostasis disorders.
- Global Footprint Expansion: Volition's Chief Commercial Officer, Gael Forterre, stated that by partnering with Sysmex, Volition aims to leverage the company’s extensive global footprint, regulatory expertise, and massive installed base of automated analyzers to enhance market penetration and optimize its technology.
See More
VolitionRx Partners with Sysmex to Optimize Nu.Q® NETs Assay
- Collaboration Agreement: VolitionRx has entered into a partnership with Sysmex, a global leader in in vitro diagnostics, to optimize its Nu.Q® NETs H3.1 assay, leveraging Sysmex's expertise in specific diseases and product development to enhance the assay's market competitiveness.
- Significant Market Potential: The Nu.Q® NETs assay has a Total Addressable Market of $3.8 billion, indicating its critical role in clinical decision-making and personalized care, which is expected to provide substantial commercial opportunities for Volition.
- Successful Technology Transfer: Following the successful transfer of the Nu.Q® NETs assay to the Sysmex platform, the collaboration has entered the optimization phase, focusing on diseases associated with NETosis, such as sepsis, thereby enhancing the clinical utility of the assay.
- Long-term Partnership Outlook: VolitionRx is optimistic about the long-term partnership with Sysmex, believing that this collaboration will not only improve diagnostic information for patients but also provide low-cost monitoring solutions, positioning the company favorably in the rapidly evolving in vitro diagnostics market.
See More
VolitionRx Announces Public Offering Plan
- Offering Details: VolitionRx plans to issue 2.96 million shares of common stock and 1.48 million warrants at a price of $1.55 per share, expecting gross proceeds of approximately $4.6 million, indicating the company's active engagement in capital markets and financing capabilities.
- Warrant Terms: Each warrant has an exercise price of $1.55, is immediately exercisable, and expires five years post-issuance, providing investors with future appreciation potential while potentially generating an additional $2.3 million in revenue for the company.
- Underwriter Participation: Maxim Group LLC acts as the sole placement agent for this offering, highlighting its significant role in capital markets and enhancing Volition's credibility and attractiveness to investors.
- Market Outlook: The offering is expected to close on June 9, 2026, and if successful, will provide funding for Volition's R&D and market expansion, further driving innovation and development in the field of epigenetics.
See More
VolitionRx Reports 300% Q1 Revenue Growth and Key Developments
- Significant Revenue Growth: In Q1 2026, VolitionRx reported $1 million in revenue, marking a 300% year-over-year increase, indicating substantial progress in market demand and product acceptance, which is expected to drive ongoing growth.
- Veterinary Milestone: The company has submitted a clinical manuscript for the Nu.Q® Vet cancer test in cats, with a $5 million milestone payment anticipated upon publication, which will not only enhance the company's financial position but also strengthen its competitiveness in the veterinary market.
- Global Licensing Momentum: VolitionRx is actively engaged in discussions with over a dozen leading global diagnostic and liquid biopsy companies, highlighting the attractiveness of its technology and potential commercial partnerships that could accelerate market integration.
- Breakthrough in Cancer Detection Technology: The Capture-Seq™ platform has demonstrated over 95% sensitivity in detecting Stage I and II cancers, opening new opportunities in the $23 billion cancer detection market and further solidifying its leadership position in the biotechnology sector.
See More
VolitionRX Reports Significant Q1 2026 Revenue Growth
- Significant Revenue Growth: VolitionRX Ltd (VNRX) reported approximately $1 million in revenue for Q1 2026, a 300% increase from $0.2 million in Q1 2025, primarily driven by deferred revenue recognition from a new QVET agreement with HESCA, indicating strong growth potential in the veterinary business.
- Rising Operating Expenses: Operating expenses increased to $6.3 million in Q1 2026 from $5.8 million in Q1 2025, partly due to severance costs and higher R&D expenses, which may exert short-term pressure on the company's profitability.
- Cash Flow Situation: The net cash used in operating activities rose to $5.3 million in Q1 2026, compared to $4.3 million in the same period last year, reflecting changes in supplier payment timing that could impact the company's liquidity management.
- Expansion of Collaboration Network: The company has entered into a non-exclusive agreement with Medical and Biological Labs Co. in Japan to accelerate disease research and drug development, demonstrating VNRX's proactive efforts to expand its partner network and market influence.
See More
VolitionRx Limited Reports Q1 2026 Earnings with Key Milestones
- Significant Revenue Growth: VolitionRx reported approximately $1 million in revenue for Q1 2026, a 400% increase from $0.2 million in the same period of 2025, primarily driven by a rise in deferred revenue recognition from the Nu.Q Vet agreement with Heska, indicating strong potential in the veterinary diagnostics market.
- Rising Operating Expenses: Operating expenses for the quarter reached $6.3 million, including severance costs related to cost reduction actions and increased R&D expenses, while cash and cash equivalents stood at $3.1 million, highlighting challenges in cost control and R&D advancement.
- Accelerated Clinical Progress: CEO Cameron Reynolds emphasized strong progress in Nu.Q Vet automation, having completed validation of the chemiluminescent immunoassay, which is expected to significantly enhance lab efficiency and potentially unlock a $5 million contractual milestone payment, further driving revenue growth.
- Cautious Future Outlook: Management stated that they will not provide revenue guidance for 2026, emphasizing the lumpiness of revenues, and indicated plans to engage with regulatory authorities in the coming months to advance reimbursement for Nu.Q Lung Cancer, reflecting uncertainty on the commercialization path.
See More
VolitionRx Partners with Sysmex for Diagnostic Optimization
- Strategic Collaboration: VolitionRx Limited (VNRX) has entered into a strategic collaboration agreement with global in vitro diagnostics leader Sysmex Corporation (SSMXF) to optimize Volition's proprietary Nu.Q® NETs H3.1 assay for automated processing on Sysmex's specialized testing platforms.
- Significant Market Potential: According to internal estimates, Volition projects the total addressable market for the specialized Nu.Q® NETs assay to be approximately $3.8 billion, indicating a vast opportunity for this technology in the healthcare market.
- Targeted Disease Focus: The partnership will primarily target diseases closely associated with NETosis, the process by which Neutrophil Extracellular Traps are released, which serves as a critical biomarker implicated in a wide range of acute and chronic conditions, including sepsis, thrombosis, and hemostasis disorders.
- Global Footprint Expansion: Volition's Chief Commercial Officer, Gael Forterre, stated that by partnering with Sysmex, Volition aims to leverage the company’s extensive global footprint, regulatory expertise, and massive installed base of automated analyzers to enhance market penetration and optimize its technology.
See More
VolitionRx Partners with Sysmex to Optimize Nu.Q® NETs Assay
- Collaboration Agreement: VolitionRx has entered into a partnership with Sysmex, a global leader in in vitro diagnostics, to optimize its Nu.Q® NETs H3.1 assay, leveraging Sysmex's expertise in specific diseases and product development to enhance the assay's market competitiveness.
- Significant Market Potential: The Nu.Q® NETs assay has a Total Addressable Market of $3.8 billion, indicating its critical role in clinical decision-making and personalized care, which is expected to provide substantial commercial opportunities for Volition.
- Successful Technology Transfer: Following the successful transfer of the Nu.Q® NETs assay to the Sysmex platform, the collaboration has entered the optimization phase, focusing on diseases associated with NETosis, such as sepsis, thereby enhancing the clinical utility of the assay.
- Long-term Partnership Outlook: VolitionRx is optimistic about the long-term partnership with Sysmex, believing that this collaboration will not only improve diagnostic information for patients but also provide low-cost monitoring solutions, positioning the company favorably in the rapidly evolving in vitro diagnostics market.
See More
VolitionRx Announces Public Offering Plan
- Offering Details: VolitionRx plans to issue 2.96 million shares of common stock and 1.48 million warrants at a price of $1.55 per share, expecting gross proceeds of approximately $4.6 million, indicating the company's active engagement in capital markets and financing capabilities.
- Warrant Terms: Each warrant has an exercise price of $1.55, is immediately exercisable, and expires five years post-issuance, providing investors with future appreciation potential while potentially generating an additional $2.3 million in revenue for the company.
- Underwriter Participation: Maxim Group LLC acts as the sole placement agent for this offering, highlighting its significant role in capital markets and enhancing Volition's credibility and attractiveness to investors.
- Market Outlook: The offering is expected to close on June 9, 2026, and if successful, will provide funding for Volition's R&D and market expansion, further driving innovation and development in the field of epigenetics.
See More
VolitionRx Reports 300% Q1 Revenue Growth and Key Developments
- Significant Revenue Growth: In Q1 2026, VolitionRx reported $1 million in revenue, marking a 300% year-over-year increase, indicating substantial progress in market demand and product acceptance, which is expected to drive ongoing growth.
- Veterinary Milestone: The company has submitted a clinical manuscript for the Nu.Q® Vet cancer test in cats, with a $5 million milestone payment anticipated upon publication, which will not only enhance the company's financial position but also strengthen its competitiveness in the veterinary market.
- Global Licensing Momentum: VolitionRx is actively engaged in discussions with over a dozen leading global diagnostic and liquid biopsy companies, highlighting the attractiveness of its technology and potential commercial partnerships that could accelerate market integration.
- Breakthrough in Cancer Detection Technology: The Capture-Seq™ platform has demonstrated over 95% sensitivity in detecting Stage I and II cancers, opening new opportunities in the $23 billion cancer detection market and further solidifying its leadership position in the biotechnology sector.
See More
VolitionRX Reports Significant Q1 2026 Revenue Growth
- Significant Revenue Growth: VolitionRX Ltd (VNRX) reported approximately $1 million in revenue for Q1 2026, a 300% increase from $0.2 million in Q1 2025, primarily driven by deferred revenue recognition from a new QVET agreement with HESCA, indicating strong growth potential in the veterinary business.
- Rising Operating Expenses: Operating expenses increased to $6.3 million in Q1 2026 from $5.8 million in Q1 2025, partly due to severance costs and higher R&D expenses, which may exert short-term pressure on the company's profitability.
- Cash Flow Situation: The net cash used in operating activities rose to $5.3 million in Q1 2026, compared to $4.3 million in the same period last year, reflecting changes in supplier payment timing that could impact the company's liquidity management.
- Expansion of Collaboration Network: The company has entered into a non-exclusive agreement with Medical and Biological Labs Co. in Japan to accelerate disease research and drug development, demonstrating VNRX's proactive efforts to expand its partner network and market influence.
See More
VolitionRx Limited Reports Q1 2026 Earnings with Key Milestones
- Significant Revenue Growth: VolitionRx reported approximately $1 million in revenue for Q1 2026, a 400% increase from $0.2 million in the same period of 2025, primarily driven by a rise in deferred revenue recognition from the Nu.Q Vet agreement with Heska, indicating strong potential in the veterinary diagnostics market.
- Rising Operating Expenses: Operating expenses for the quarter reached $6.3 million, including severance costs related to cost reduction actions and increased R&D expenses, while cash and cash equivalents stood at $3.1 million, highlighting challenges in cost control and R&D advancement.
- Accelerated Clinical Progress: CEO Cameron Reynolds emphasized strong progress in Nu.Q Vet automation, having completed validation of the chemiluminescent immunoassay, which is expected to significantly enhance lab efficiency and potentially unlock a $5 million contractual milestone payment, further driving revenue growth.
- Cautious Future Outlook: Management stated that they will not provide revenue guidance for 2026, emphasizing the lumpiness of revenues, and indicated plans to engage with regulatory authorities in the coming months to advance reimbursement for Nu.Q Lung Cancer, reflecting uncertainty on the commercialization path.
See More
